Indo-City Info. (532100)
Fast GrowerScore breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹13.95 |
| Market Cap | ₹15.11 Cr |
| P/E Ratio | 22 |
| ROCE | -10.22% |
| ROE | 4.44% |
| Dividend Yield | 0% |
| Profit Growth | 195% |
| Debt/Equity | — |
| Sales Growth | 111.32% |
| 52-Week Range | ₹9.95 — ₹14.08 |
| Sector | IT - Software |
| Book Value | ₹10.87 |
Strengths
- Sales growth of 111.32% and profit growth of 195% show strong momentum.
- Latest quarter sales of ₹4 Cr and net profit of ₹1 Cr indicate improved profitability.
- P/B of 1.28 with book value of ₹10.87 provides some downside support.
- Piotroski F-Score of 6/9 suggests improving financial fundamentals.
- PEG of 0.14 appears undemanding if current growth persists.
Concerns
- ROE of only 4.44% and ROCE of -10.22% signal poor returns on equity and capital.
- P/E of 22 is rich for a company with such low profitability and no dividend.
- Promoter holding and debt/equity data are not disclosed, leaving governance and leverage risks unknown.
- Microcap size of ₹15 Cr with volatile quarterly figures; growth may be from a low base.
AI Analysis
At ₹13.95, Indo-City Info is a microcap story, priced at 22 times earnings with a market cap of only ₹15 Cr. The headline numbers are electrifying — sales up 111% and profit up 195% — and the latest quarter shows ₹4 Cr revenue with ₹1 Cr net profit. But Graham taught me to weigh figures, not headlines. A 4.44% ROE and a negative -10.22% ROCE tell me this business does not yet earn attractive returns on the capital it employs. The 1.28 price-to-book offers some asset support, but book value of ₹10.87 is not a margin of safety if returns stay this weak. The PEG of 0.14 appears cheap only if 111% growth is durable; small software product companies often grow in irregular spurts, and a ₹15 Cr market cap can be whipsawed easily. There is no dividend to reward patience, and promoter holding is not disclosed, which is a red flag for minority shareholders in India. The Piotroski score of 6 out of 9 suggests improving fundamentals, but not a clean bill of health. I would not call this a great business; it is a small, fast-growing enterprise with poor capital efficiency and an unproven moat. At 22 times earnings, the market is already paying for continued perfection. If I owned it, I would watch every quarter for cash conversion and margin quality. If I didn't, I would let the price come down or the ROCE turn positive before treating it as a serious value investment. Growth is exciting, but as Buffett says, price is what you pay; value is what you get. Right now, I don't see enough value evidence.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer